4014-90-8

Basic information

• Product Name: 2-amino-6-benzylaminopurine
• Synonyms: 2-amino-6-benzylaminopurine
• CAS NO: 4014-90-8
• Molecular Weight: 240.267
• Mol File: 4014-90-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-amino-6-benzylaminopurine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-6-benzylaminopurine(4014-90-8)
• EPA Substance Registry System: 2-amino-6-benzylaminopurine(4014-90-8)

Safety Data

• Hazardous Substances Data: 4014-90-8(Hazardous Substances Data)

Usage

Properties

Synthetic cytokinin
Stimulates cell division
Promotes shoot and root growth
Potential applications in agriculture, horticulture, and biotechnology
Investigated for potential pharmacological and pharmaceutical applications

Specific content

Derivative of natural plant hormone cytokinin
Commonly used in plant tissue culture
Enhances plant growth and improves crop yields
Investigated as an anticancer agent and for other medical treatments

Upstream product

• 26783-32-4 2-amino-6-(benzylamino)-9-(β-D-ribofuranosyl)purine 
• 100-46-9 benzylamine 
• 10310-21-1 2-amino-6-chloropurine 
• 10310-21-1 2-Amino-6-chloropurin 
• 154-42-7 thioguanin 
• 1198-47-6 6-Methylthioguanine 

Downstream Products

• 3800-23-5 N-benzyl-2-fluoro-9H-purin-6-amine 
• 1395875-36-1 N⁶-benzyl-N²-(4-bromophenyl)-9H-purine-2,6-diamine 
• 1395875-39-4 N⁶-benzyl-N²-(4-methoxyphenyl)-9H-purine-2,6-diamine 
• 1395875-42-9 N⁶-benzyl-N²-(p-tolyl)-9H-purine-2,6-diamine 
• 1395875-58-7 N⁶-benzyl-N²-phenyl-9H-purine-2,6-diamine 
• 1395875-49-6 N⁶-benzyl-N²-(4-hydroxyphenyl)-9H-purine-2,6-diamine 
• 1395875-52-1 N⁶-benzyl-N²-(4-fluorophenyl)-9H-purine-2,6-diamine 
• 1395875-55-4 4-(6-(benzylamino)-9H-purine-2-ylamino)benzenesulfonamide 
• 1395875-61-2 N⁶-benzyl-N²-(4-(methylsulfonyl)phenyl)-9H-purine-2,6-diamine 
• 1395875-45-2 N⁶-benzyl-N²-(3-methoxyphenyl)-9H-purine-2,6-diamine 
• 134444-71-6 2-Amino-6-benzylamino-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)-9H-purine 
• 158982-11-7 2-amino-6-benzylamino-9-purine 

Relevant articles and documents

Chemoenzymatic synthesis of cytokinins from nucleosides: Ribose as a blocking group

Nucleoside phosphorylases are involved in the salvage pathways of nucleoside biosynthesis and catalyze the reversible reaction of a nucleobase with α-d-ribose-1-phosphate to yield a corresponding nucleoside and an inorganic phosphate. The equilibrium of these reactions is shifted towards nucleosides, especially in the case of purines. Purine nucleoside phosphorylase (PNP, EC 2.4.2.1) is widely used in labs and industry for the synthesis of nucleosides of practical importance. Bacterial PNPs have relatively broad substrate specificity utilizing a wide range of purines with different substituents to form the corresponding nucleosides. To shift the reaction in the opposite direction we have used arsenolysis instead of phosphorolysis. This reaction is irreversible due to the hydrolysis of the resulting α-d-ribose-1-arsenate. As a result, heterocyclic bases are formed in quantitative yields and can be easily isolated. We have developed a novel method for the preparation of cytokinins based on the enzymatic cleavage of the N-glycosidic bond of N6-substituted adenosines in the presence of PNP and Na2HAsO4. According to the HPLC analysis the conversion proceeds in quantitative yields. In the proposed strategy the ribose residue acts as a protective group. No contamination of the final products with AsO43- has been detected via HPLC-HRMS; simple analytical arsenate detection via ESI-MS has been proposed.

IMAGING AGENTS FOR NEURAL FLUX

Provided herein are radiolabeled compounds useful for non-invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography. The present application also provides unlabeled compounds useful in methods of treating diseases of the central nervous system or disease of the peripheral nervous system. Methods for preparing radiolabeled compounds, preparing unlabeled compounds, and diagnostic methods using labeled or unlabeled compounds are also provided.

Design, synthesis and preliminary biological evaluation of purine-2,6-diamine derivatives as cyclin-dependent kinase (CDK) inhibitors

Novel purine-2,6-diamine derivatives were designed and synthesized as cyclin-dependent kinase (CDK) inhibitors. According to the preliminary biological evaluation, most of the compounds show good inhibitory activities in CDK1 enzyme assay and potent antiproliferative activities in some tumor cell lines. Especially, compound 11a (IC50=0.35 μmol/L for CDK1/cyclin B and IC50=0.023 μmol/L for CDK2/cyclin A) possessed better inhibitory effect compared with Roscovitine (IC50=2.54 (mol/L for CDK1/cyclin B and IC50=0.092 μmol/L for CDK2/cyclin A). Copyright